PIDTC: Investigating Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with P47phox Chronic Granulomatous Disease
24 de abr. de 2024 ·
2m 3s
Regístrate gratis
Escucha este episodio y muchos más. ¡Disfruta de los mejores podcasts en Spreaker!
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Descripción
New research from the Primary Immune Deficiency Treatment Consortium (PIDTC). This summary is based on a paper published in the Journal of Allergy and Clinical Immunology on January 28, 2024,...
mostra más
New research from the Primary Immune Deficiency Treatment Consortium (PIDTC). This summary is based on a paper published in the Journal of Allergy and Clinical Immunology on January 28, 2024, titled "Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study."
Read the paper here: https://www.jacionline.org/article/S0091-6749(24)00081-2/abstract
Learn more about PIDTC: https://pidtc.rarediseasesnetwork.org
mostra menos
Read the paper here: https://www.jacionline.org/article/S0091-6749(24)00081-2/abstract
Learn more about PIDTC: https://pidtc.rarediseasesnetwork.org
Información
| Autor | RDCRN |
| Organización | RDCRN |
| Página web | - |
| Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
